The findings of high IDO1 levels in several cancers and studies showing that IDO1 is critical for tumor survival has led to intense interest in the potential of anti-IDO1 based immunomodulatory therapeutics [55], [56], [57], [58]. Here, IDO1 is linked to cancer.